Palliative chemotherapy and radiotherapy for metastatic colorectal cancer;Palliativ kjemoterapi og strålebehandling ved metastatisk kolorektal cancer

Tidsskrift for den Norske Laegeforening

Volumn 128, Issue 2, 2008, Pages 194-197

  Sørbye, Halfdan ^a   Brændengen, Morten ^b   Balteskard, Lise ^c  

^a Kreftavdelingen   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c Universitetssykehuset Nord Norge ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BEVACIZUMAB; CAMPTOTHECIN; CETUXIMAB; DRUG DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX;

ADULT; AGED; COLORECTAL TUMOR; HUMAN; METASTASIS; METHODOLOGY; MIDDLE AGED; PALLIATIVE THERAPY; QUALITY OF LIFE; REVIEW; SURVIVAL RATE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; QUALITY OF LIFE; SURVIVAL RATE;

EID: 38749121372     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Norsk Gastrointestinal Cancer Gruppe. www.ngicg.no (1.2.2007).
2. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer. J Clin Oncol 1992; 10: 904-11.
3. Norges offentlige utredninger. Omsorg og kunnskap - Norsk kreftplan. NOU 1997: 20.
4. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-91.
5. Köhne CH, Cunningham D, Di Costanzo F et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer. Ann Oncol 2002; 13: 308-17.
6. Sørbye H, Glimelius B, Berglund Å et al. Multicentre phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2004; 22: 31-8.
7. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553-60.
8. Glimelius B, Jakobsen A, Graf W et al. Bolus injection versus short-term infusion of 5-fluorouracil in patients with advanced colorectal cancer. Eur J Cancer 1998; 34: 674-9.
9. Glimelius B, Ristamäki R, Kjaer M et al. Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. Ann Oncol 2002; 13: 1868-73.
10. Cassidy J, Tabernero J, Twelves C et al. XELOX: active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084-91.
11. Pfeiffer P, Sørbye H, Ehrsson H et al. Short-time infusion of oxaliplatin in combination with capecitabine as second line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Ann Oncol 2006; 17: 252-8.
12. Glimelius B, Sørbye H, Balteskard L et al. Randomised phase III multicenter trial comparing irinotecan in combination with Nordic bolus 5FU or the bolus/infused deGramont schedule, in patients with metastatic colorectal cancer. Ann Oncol 2007; akseptert for publisering.
13. Pfeiffer P, Mortensen JP, Bjerregaard B et al. Patient preference for oral or intravenous chemotherapy. Eur J Can 2006; 42: 2738-43.
14. Sørbye H, Berglund Å, Tveit KM et al. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. Acta Oncol 2007; 46: 982-8.
15. Grothey A, Sargent D, Goldberg RM et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-14.
16. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
17. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with XELOX or FOLFOX4.Gastrointestinal Cancers Symposium 2007; abstract 238. www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/? vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview= abst_detail_view&confID=45&abstractID=10580 (22.11.2007).
18. Giantonio BJ, Catalano PJ, Meropol NJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer. J Clin Oncol 2007; 25: 1539-44.
19. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
20. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-16.
21. Nordlinger B, Brouquet A, Penna C et al. Complete radiological response of colorectal liver metastases after chemotherapy: Does it mean cure? Proc Am Soc Clin Oncol 2006; abstract 3501. www.asco.org/portal/site/ASCO/menuitem. 34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 40&abstractID=32505 (22.11.2007).
22. Sørbye H, Dahl O. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy. J Clin Oncol 2003; 21: 4466-7.
23. Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy. Ann Surg 2004; 204: 644-58.
24. Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24: 2065-72.
25. Kozloff M, Cohn A, Christiansen N et al. Safety of bevacizumab among patients receiving first-line chemotherapy for metastatic colorectal cancer (BRiTE). Proc Am Soc Clin Oncol 2006; abstract 247. www.asco.org/portal/site/ ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid= 76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID= 41&abstractID=405 (22.11.2007).
26. Glimelius B, Gronberg H, Jarhult J et al. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol 2003; 42: 476-92.
27. Mohiuddin M, Marks G, Marks J. Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer 2002; 95: 1144-50.
28. Valentini, Moraganti AG, Gambacorta MA et al. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis. Int J Radiat Oncol Biol Phys 2006; 64: 1129-39.
29. Chow E, Harris K, Fan G et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007; 25: 1423-36.
30. Chang JE, Robins HI, Mehta MP. Therapeutic advances in the treatment of brain metastases. Clin Adv Hematol Oncol 2007; 5: 54-64.
31. Timmerman RD, Kavanagh BD, Cho LC et al. Stereotactic body radiation therapy in multiple organ sites. J Clin Oncol 2007; 25: 947-52.